|Bid||0.00 x 900|
|Ask||0.00 x 1300|
|Day's Range||60.64 - 62.77|
|52 Week Range||34.75 - 94.34|
|Beta (3Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.18|
Nevro Corp. (NVRO) is among a host of public and private companies marketing or developing medical devices to treat pain. Warning! GuruFocus has detected 2 Warning Signs with NVRO. Medical device companies that can help reduce opioid use promise to be rewarded handsomely and merit the attention of savvy investors.
Nevro Corp (NYSE: NVRO ) announced a series of board changes and the appointment of a new CEO after the close Tuesday. The medical device company's stock was surging Wednesday on the news. The changes ...
Check out the companies making headlines midday Wednesday:FedEx FDX — Shares of FedEx dropped 5.14 percent after the company reported lower-than-expected third-quarter earnings and reduced its earnings outlook for fiscal year 2019.
In a statement, Nevro said that it has appointed Keith Grossman as president and CEO, succeeding Rami Elghandour. Grossman was previously president and CEO of Thoratec, another medical device manufacturer, leading up to its 2015 sale to St. Jude Medical.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 19) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...
REDWOOD CITY, Calif., March 19, 2019 /PRNewswire/ -- Nevro Corp. (NVRO) ("Nevro"), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman has been appointed President and Chief Executive Officer of Nevro and a member of the Board of Directors (the "Board"), effective today. Mr. Grossman succeeds Rami Elghandour, who has stepped down as President, CEO and a director of the Company.
The Redwood City, California-based company said it had a loss of 32 cents per share. The results missed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research ...
Nevro (NVRO) delivered earnings and revenue surprises of -88.24% and 0.53%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
REDWOOD CITY, Calif. , Feb. 21, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today ...
REDWOOD CITY, Calif. , Feb. 15, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today ...
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nevro Corp NYSE:NVROView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for NVRO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding NVRO totaled $1.94 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Company to Host Conference Call on Thursday, February 21, 2019 at 1:30 p.m. PT / 4:30 p.m. ET REDWOOD CITY, Calif. , Feb. 7, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company ...
NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
In 2016 Rami Elghandour was appointed CEO of Nevro Corp. (NYSE:NVRO). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Read More...
LOS ANGELES, Jan. 10, 2019 -- Glancy Prongay & Murray LLP (“GPM”) announces that it is investigating potential claims on behalf of investors of Nevro Corp. (NYSE: NVRO).
REDWOOD CITY, Calif., Jan. 7, 2019 /PRNewswire/ -- Nevro Corp. (NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2018. The company announced that preliminary unaudited fourth quarter 2018 worldwide revenue is expected to be in the range of $107.6 to $108.1 million, compared to $98.0 million in the prior year quarter. Preliminary unaudited U.S. revenue for the fourth quarter of 2018 is expected to be in the range of $91.5 to $91.8 million, compared to $81.1 million in the prior year quarter. Preliminary unaudited international revenue for the fourth quarter of 2018 is expected to be in the range of $16.1 to $16.3 million, compared to $16.9 million in the prior year quarter.
REDWOOD CITY, Calif. , Dec. 20, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, ...
When Nevro Corp. (NYSE:NVRO) announced its most recent earnings (30 September 2018), I compared it against two factor: its historical earnings track record, and the performance of its industry peers Read More...